Many thanks to the University of Colorado Cancer Center for interviewing us about our recent multicenter study published in Blood Advances about checkpoint inhibitor efficacy in the post-CAR-T relapse setting. #lymsm

https://news.cuanschutz.edu/cancer-center/lymphoma-treatment-after-car-t-therapy-fails

The March #StemCellEvidence Alert is out! If you don't receive it free in your inbox, sign up and see this month's top ten references here: http://www.stemcellevidence.com/alerts
#BMT #leusm #mmsm #lymsm

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma

https://pubmed.ncbi.nlm.nih.gov/36821767/

#Lymphoma #MEDMASTODON @majorajay #lymsm

Review of first-line treatments for advanced anaplastic lymphoma kinase mutated, non-small cell cancer

PS I'm available (for a fee) to draft plain language summaries. This is not how I'd explain the results to grandma.

https://pubmed.ncbi.nlm.nih.gov/36748799/

in a 52-patient study, emotional well-being continues to be an unmet need during active surveillance of patients with indolent NHL (compared to norm general population scores)

#MEDMASTODON #lymphoma #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

https://pubmed.ncbi.nlm.nih.gov/36120910/

Three of those four #lymphoma patients achieved a complete response with out-of-commercial specification (OOS) CAR T therapy

Risk factors for OOS were ≥ 4 prior therapies or previous bendamustine exposure.

#MEDMASTODON #Cancer
#ClinicalResearch #Oncology #Medicine #lymsm @majorajay

https://pubmed.ncbi.nlm.nih.gov/36111694/

PFS is a surrogate for OS in DLBCL, one of the few actual validated surrogate endpoints: https://pubmed.ncbi.nlm.nih.gov/29975624/ #lymsm

RT @graham74GC@twitter.com

Pola-R-CHP has been approved by NICE for front line treatment of DLBCL in IPI 2-5. This means hospitals in England are legally obliged to offer it so this will become a new standard. More thoughts in thread.
#lymsm

https://www.nice.org.uk/guidance/indevelopment/gid-ta10785/documents

Our top article this month is Hermine et al in @JCO_ASCO High-Dose Cytarabine and AutoHSCTin Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial. http://www.stemcellevidence.com/article/36469833 #BMT #StemCellEvidence
#BMT #lymsm #StemCellEvidence

#MEDMASTODON #lymphoma #Cancer #lymsm @majorajay

Report on the curative potential of autologous stem cell rescue following high dose chemotherapy for relapsed follicular lymphoma

https://pubmed.ncbi.nlm.nih.gov/36625160/

Deeply honored that our @ASH_hematology@twitter.com #ASH22 abstract on outcomes of checkpoint inhibitors after post-CAR-T relapse will be featured in Highlights of ASH. Many thanks to all our collaborators. Manuscript is on the way! ✍🏽✍🏽#lymsm #celltherapy

Excellent thread about BITEs in #lymsm & #mmsm by Dr. @mihematology@twitter.com. Will be very interesting to see how these settle in sequence with CAR. #celltherapy

RT @mihematology@twitter.com

I put together a talk on bispecific T cell engagers in lymphoma and myeloma for @UMNHOT@twitter.com grand rounds last week

Here’s a quick overview of the four phase 2 BiTE trials published in 2022 including:

• Glofitamab
• Epcoritamab
• Mosunetuzumab
• Teclistamab

🧵(1/7)

Check out these beautiful CD20+ and CD20- aggressive lymphoma classification algorithms from Dr. Pan being presented at our @CULymphoma@twitter.com tumor board. Saving these for future reference! #lymsm #hemepath https://t.co/Awfv6CtInc

Fantastic summary slides on WHO vs ICC aggressive lymphoma classification differences (including DHL) from our @CULymphoma@twitter.com tumor board today. #lymsm #hemepath cc @mana1981@twitter.com @BradHaverkos@twitter.com @StevenBairMD@twitter.com https://t.co/jcLcO0wZsq

Large retrospective cohort of rare #lymsm: 41 pts with B-PLL. 40% asx at dx; these pts with superior OS & less high risk features. TP53mut = worse survival. Better PFS (not OS) in TP53mut (F below) with BTKi compared to CIT, with mPFS still only 2 yrs. https://haematologica.org/article/view/haematol.2022.282162

Update: interim PET after 3 cycles of DA-R-EPOCH with CMR! LVEF preserved, no arrhythmias (I left out the initial detail that presentation was after out-of-hospital cardiac arrest), no perforation (held ritux for C1). #lymsm

RT @majorajay@twitter.com

Another lymphoma poll! How do you manage fit primary cardiac DLBCL with classic presentation with RV wall mass and arrhythmias? #lymsm

Tough case for #lymsm: 60-something with bulky double hit lymphoma with extensive extranodal dx. Strong suspicion for leptomeningeal involvement given invasion into spinal canal. EPOCH planned. If CSF+, how would you treat CNS involvement?

#MEDMASTODON #lymphoma #Cancer #lymsm @majorajay

Can't see how this is useful. Can someone explain? The need is for tests predictive of efficacy before treatment.

=> Deauville score and quantitative PET scan parameters as a predictive tool of anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy

https://pubmed.ncbi.nlm.nih.gov/36385707/

Hey #lymsm folks: I'm giving a post-ASH review talk on lymphoma updates from #ASH22, and I wanted to crowdsource the most important & high-yield lymphoma abstracts from @ASH_hematology@twitter.com this year. Please comment below! #celltherapy

Cracked open my mother's clinical oncology book from 1978 (just 327 pages!). Check out the chapter on "The Malignant Lymphomas, Multiple Myeloma, and Macroglobulinemia" and all these regimens! Totally fascinating. #lymsm #mmsm

#lymphoma #Cancer #lymsm @majorajay #lymsm

FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma

https://www.gene.com/media/press-releases/14978/2022-12-22/fda-approves-genentechs-lunsumio-a-first